Loading...
NPI 1053303362 · Fogelsville, PA · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Thucanh Multerer is a retina specialist (ophthalmology) physician provider located in Fogelsville, Pennsylvania. This profile covers 12 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Thucanh Multerer |
| Address | 1431 Nursery St Ste 200 |
| City | Fogelsville |
| State | PA |
| ZIP | 18051 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | August 22, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $862.9K |
| Medicaid | $139.4K |
Practice is tightly focused on intravitreal anti-VEGF therapy and related retinal procedures: the provider’s top Medicare revenue driver is J0178 (aflibercept injection) with 949 claims generating $653.9K, and other leading Medicare codes include J2777 (faricimab) and 67028 (intravitreal injection procedure). This code mix is consistent with a retina specialist whose revenue is primarily generated by in-office injectable therapies and the associated procedure codes rather than high volumes of diverse surgical procedures.
Revenue is highly concentrated in a small set of injection-related codes across both payers: the top 3 Medicare codes account for 91.0% of Medicare revenue and the top 3 Medicaid codes account for 92.2% of Medicaid revenue. That concentration indicates the business is operationally dependent on a narrow service line (anti-VEGF injections and immediate procedural support), which can simplify payer negotiations but increases exposure to changes in drug access or reimbursement for those codes.
Medicare is the dominant payer by scale for this clinician: total Medicare revenue is $862.9K versus total Medicaid revenue of $139.4K. The gap shows this provider operates with a primarily Medicare patient base while Medicaid contributes a meaningful but much smaller share of overall revenue.
J0178 shows a solid but not dominant competitive standing: on Medicare the code produced $653.9K and ranks #1334 of 3204 providers (58th percentile, described as typical, unremarkable volume), while on Medicaid J0178 produced $94.4K across 79 claims and ranks #23 of 41 in-state (43th percentile, typical, unremarkable volume). Note the per-claim payments differ by payer for this drug (Medicare avg paid/claim $689 vs. Medicaid avg paid/claim $1195), reflecting material payer-level price differences even with much lower Medicaid claim volume.
J2777 (faricimab) and 67028 show different comparative footprints: J2777 accounts for $81.8K on Medicare from 2.8K claims but ranks #1863 of 2039 providers (8th percentile, typical, unremarkable volume), indicating a modest-to-low comparative presence nationally for that code despite substantive claim counts; 67028 accounts for $49.4K on Medicare (617 claims, rank #1958 of 4255, 54th percentile) and $28.7K on Medicaid (150 claims, rank #62 of 99, 38th percentile), reflecting routine use of isolated intravitreal injection procedures in both payers. These placements suggest routine procedural throughput rather than market leadership in either payer population.
The practice demonstrates above-average retinal imaging and evaluation-and-management activity relative to broad peer sets: Medicare 92134 produced 935 claims and $21.5K in revenue and ranks #2274 of 26868 providers (92th percentile, typical, unremarkable volume), while evaluation-and-management codes 99213 and 99214 appear at high national percentiles (90th and 82th, respectively) with 352 and 339 Medicare claims. This pattern signals that the clinician combines frequent diagnostic imaging and steady office visit volumes with injection work, consistent with a diagnostic-and-treatment ambulatory retina practice.
Tenure is substantial: the NPI was enumerated on 2005-08-22 (~21 years ago), indicating long-term presence in the market. Long tenure can support established referral relationships and predictable patient panels, which is relevant when assessing network continuity or contracting risk.
Smaller revenue contributors include laser photocoagulation (67228) and ancillary imaging codes (92235, 92250) and injectable bevacizumab (J9035) which together make up modest percentages of payer-specific revenue. The presence of 67228 on both payers (Medicare $6.2K; Medicaid $5.5K) indicates occasional treatment of retinopathy with laser in addition to the dominant anti-VEGF injection business, showing some breadth in retinal therapeutic capability.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 950 | $690 | $653.9K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 2,820 | $30 | $81.8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 620 | $80 | $49.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 940 | $20 | $21.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 350 | $60 | $19.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 340 | $50 | $15.6K |
| 67228 | In retinopathy, tiny new vessels grow profusely and fibrous tissue proliferates in between the layers of the retina, which may extend into the optic nerve and vitreous, clear gel that fills the space… | 30 | $250 | $6.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 60 | $80 | $4.6K |
| J9035 | Injection, bevacizumab, 10 mg | 70 | $50 | $3.9K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 50 | $70 | $3.6K |
Showing 1–10 of 12
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
12 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 16 | 140 | 830 | $690 | $865.1K |
| J2777 | 26 | 100 | 7,950 | $30 | $360.2K |
| 67028 | 38 | 180 | 600 | $90 | $87.5K |
| 92014 | 504 | 1,570 | 130 | $80 | $21K |
| 99214 | 690 | 23,230 | 100 | $80 | $14.5K |
| 92235 | 15 | 70 | 40 | $100 | $10K |
| J9035 | 47 | 60 | 80 | $50 | $8.7K |
| 92134 | 32 | 1,320 | 60 | $30 | $8.4K |
| 99213 | 281 | 22,370 | 70 | $60 | $7.7K |
| 67228 | 5 | 20 | 20 | $230 | $5.4K |
Showing 1–10 of 12
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 80 | $1,200 | $94.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 150 | $190 | $28.6K |
| 67228 | In retinopathy, tiny new vessels grow profusely and fibrous tissue proliferates in between the layers of the retina, which may extend into the optic nerve and vitreous, clear gel that fills the space… | 20 | $320 | $5.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 260 | $20 | $4.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 90 | $40 | $3.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 110 | $20 | $1.9K |
| J9035 | Injection, bevacizumab, 10 mg | 30 | $50 | $1.6K |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 23 | 40 | 120 | $340 | $182.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 62 | 100 | 330 | $70 | $85.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 5,313 | 8,160 | 210 | $60 | $68.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 5,637 | 8,870 | 240 | $40 | $56.1K |
| J9035 | Injection, bevacizumab, 10 mg | 35 | 50 | 250 | $50 | $33.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 97 | 180 | 290 | $20 | $24.8K |
| 67228 | In retinopathy, tiny new vessels grow profusely and fibrous tissue proliferates in between the layers of the retina, which may extend into the optic nerve and vitreous, clear gel that fills the space… | 3 | 10 | 20 | $310 | $9.3K |
Other providers in the same ZIP code as Thucanh Multerer, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Melissa Mercado | PA | Medical Physician Assistant | $228.1K | $0 |
| Gregory Singer | PA | Family Medicine Physician | $46.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.